Inozyme Pharma nabs $49 mln Series A

Inozyme Pharma Inc, a developer of treatments for rare diseases of calcification, affecting soft tissues and bone, has raised $49 million in Series A financing. Longitude Capital led the round with participation from other investors that included New Enterprise Associates, Novo Ventures and Sanofi Ventures.

ManagersNorth AmericaUSHealthcareBriefs